In PAECs, class-2a HDAC inhibitors restore the levels of myocyte-enhancer-factor-2 and attenuate PAH in both the MCT and SuHx PAH rat models [135]. The gene discussed is HDAC9; the disease is pulmonary arterial hypertension.